Business Wire

Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist

MANCHESTER, England & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced that the first ...
Business Wire

Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist

MANCHESTER, England & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive ...
webBikeWorld

AGV AX-8 Dual EVO Review

The AX-8 Dual EVO is a redesigned version of the 2011 AGV AX-8 Dual helmet. The new version has high-quality construction and several features not found on other dual-sport helmets. It’s also quieter ...
webBikeWorld

AGV AX-8 Evo Carbon Fiber Helmet Review

These days, everyone is looking for an intimidating helmet, and in this regard the AGV AX-8 Evo Naked CARBON doesn’t disappoint. The design caters a new type of rider that spends more time on the ...
VentureBeat

Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist

AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough MANCHESTER, England & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–June 29, 2022– Axalbion, a clinical-stage ...